PROBLEM TO BE SOLVED: To provide antibodies specifically reacting with hTROP-2 and having in vivo antitumor activity, hybridomas producing the antibodies, conjugates of the antibodies and agents, pharmaceutical compositions for the diagnosis or treatment of tumors, detection methods of tumors, and kits for the detection or diagnosis of tumors.SOLUTION: The invention relates to a hybridoma immunizing a mouse with an hTROP-2 expression stable cell line or recombinant hTROP-2 protein, and producing anti-hTROP-2 monoclonal antibodies (mAb) which recognize hTROP-2 protein in accordance with a usual method. The invention also relates to antibodies whose antibody gene sequence is determined by evaluating the anti-hTROP-2-mAb (about 160 clones) using Xenograft Treatment model of pancreatic cancer cell line PK-59 cell, and obtaining antibodies and production hybridomas expressing tumor growth inhibitory activity that is significant in vivo.【課題】hTROP-2と特異的に反応しin vivoで抗腫瘍活性を有する抗体、当該抗体を産生するハイブリドーマ、当該抗体と薬剤との複合体、腫瘍の診断用又は治療用医薬組成物、腫瘍の検出方法、腫瘍の検出用又は診断用キットの提供。【解決手段】hTROP-2発現安定細胞株又はリコンビナントhTROP-2タンパク質でマウスを免疫し、常法に従いhTROP-2タンパク質を認識する抗hTROP-2モノクローナル抗体（ｍＡｂ）を産生するハイブリドーマ。抗hTROP-2ｍＡｂ(約160クローン)を膵癌細胞株PK-59細胞のXenograft Treatmentモデルで評価し、in vivoで有意な腫瘍成長阻害活性を示す抗体及び産生ハイブリドーマを取得し、抗体遺伝子配列を決定した抗体。【選択図】なし
